Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.560 +0.070 (+4.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
From Mainz BioMed NV
Via GlobeNewswire
The Latest Analyst Ratings for Mainz Biomed
 
Via Benzinga
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... 
Via Benzinga
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
From Mainz BioMed NV
Via GlobeNewswire
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System 
From Mainz BioMed NV
Via GlobeNewswire
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients 
From Mainz BioMed NV
Via GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
--News Direct-- 
Via News Direct
Topics Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... 
Via Benzinga
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the... 
Via Benzinga
Topics Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
From Mainz BioMed NV
Via GlobeNewswire
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
Mainz Biomed Provides Year-End Corporate Review 2023
From Mainz BioMed NV
Via GlobeNewswire
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
 
Via Benzinga
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in... 
Via Benzinga
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.